GB Sciences, Inc. (GBLX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, GB Sciences, Inc. (GBLX) es una empresa del sector Healthcare valorada en 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026GB Sciences, Inc. (GBLX) Resumen de Asistencia Médica y Tuberías
GB Sciences, Inc., operating in the biotechnology sector, researches and develops plant-based medicines, including cannabinoid-inspired therapies, targeting conditions like Parkinson's disease and neuropathic pain. With pre-clinical programs and a focus on complex therapeutic mixtures, the company aims to serve the prescription drug market in North America and Europe.
Tesis de Inversión
GB Sciences, Inc. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology firms. The company's focus on plant-based medicines, particularly cannabinoid-inspired therapies, aligns with growing market interest in alternative treatments. However, with a market capitalization of $0.00B and negative profitability (P/E of -0.28 and a profit margin of -299.6%), the company's financial stability is a significant concern. The company's gross margin is 100.0%. The success of GB Sciences hinges on advancing its pre-clinical programs to clinical trials and ultimately securing regulatory approvals. The high beta of 9.86 indicates extreme volatility. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty inherent in pharmaceutical development.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.00B reflects the company's small size and early stage of development.
- P/E Ratio of -0.28 indicates the company is not currently profitable.
- Profit Margin of -299.6% demonstrates significant losses relative to revenue.
- Gross Margin of 100.0% suggests high potential profitability if research and development costs can be managed effectively.
- Beta of 9.86 indicates the stock is significantly more volatile than the market average.
Competidores y Pares
Fortalezas
- Focus on plant-based medicines.
- Intellectual property portfolio.
- Pre-clinical programs targeting unmet medical needs.
- Expertise in cannabinoid-inspired therapies.
Debilidades
- Limited financial resources.
- Small team size.
- Early stage of development.
- Dependence on external funding and partnerships.
Catalizadores
- Upcoming: Announcement of results from pre-clinical studies for Parkinson's disease program (timeline: next 6-12 months).
- Upcoming: Initiation of clinical trials for neuropathic pain therapy (timeline: next 12-18 months, contingent on funding).
- Ongoing: Pursuit of strategic partnerships with larger pharmaceutical companies.
- Ongoing: Expansion of intellectual property portfolio through new patent filings.
- Ongoing: Research and development efforts to advance drug candidates through the pipeline.
Riesgos
- Potential: Failure to secure funding for clinical trials.
- Potential: Negative results from clinical trials.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from larger biotechnology companies with greater resources.
- Ongoing: Limited financial resources and dependence on external funding.
Oportunidades de crecimiento
- Advancement of Parkinson's Disease Program: GB Sciences has a pre-clinical program targeting Parkinson's disease. The Parkinson's disease treatment market is projected to reach $5.6 billion by 2027. Successfully transitioning this program to clinical trials and demonstrating efficacy could unlock significant value for the company. The timeline for this catalyst depends on securing funding and completing pre-clinical studies, potentially leading to clinical trials within the next 2-3 years.
- Development of Neuropathic Pain Therapies: The company is developing plant-based medicines for neuropathic pain, a market estimated at $8.3 billion globally. Achieving positive results in pre-clinical studies and advancing to clinical trials could position GB Sciences as a player in this large and growing market. This growth opportunity is contingent on successful pre-clinical data, which could lead to clinical trial initiation within 2-3 years.
- Expansion into Cardiovascular Therapeutics: GB Sciences has a cardiovascular therapeutic program in the pre-clinical stage. The global cardiovascular disease market is substantial, offering significant potential for new therapies. Progressing this program through pre-clinical and clinical stages could diversify the company's pipeline and create new revenue streams. This is a longer-term opportunity, with potential clinical trials 3-5 years out.
- Commercialization of COVID-Related Cytokine Release Syndrome Treatment: GB Sciences is researching treatments for COVID-related cytokine release syndrome. While the urgency of the COVID-19 pandemic has decreased, there remains a need for effective treatments for complications arising from the virus. Successful development and commercialization of such a treatment could provide a near-term revenue opportunity. This opportunity depends on ongoing research and potential regulatory pathways, possibly yielding results within the next 1-2 years.
- Strategic Partnerships and Licensing Agreements: GB Sciences can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timing and success of such partnerships are uncertain but represent a potential growth driver in the near to medium term.
Oportunidades
- Growing market for plant-based medicines.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of pre-clinical programs to clinical trials.
- Expansion into new therapeutic areas.
Amenazas
- Regulatory hurdles and approval processes.
- Competition from larger biotechnology companies.
- Uncertainty in clinical trial outcomes.
- Fluctuations in market demand for plant-based therapies.
Ventajas competitivas
- Intellectual property portfolio covering various therapeutic areas.
- Expertise in developing cannabinoid-inspired medicines.
- Focus on plant-based therapies, aligning with growing market trends.
- Proprietary formulations and drug delivery systems.
Acerca de GBLX
GB Sciences, Inc., founded in 2001 and based in Las Vegas, Nevada, is a biotechnology company dedicated to the research and development of plant-based medicines. Originally incorporated as Growblox Sciences, Inc., the company rebranded in October 2016 to reflect its evolving focus. GB Sciences develops cannabinoid-inspired medicines and complex therapeutic mixtures intended for the prescription drug market. Their research spans a range of conditions, including Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. The company's intellectual property portfolio covers these therapeutic areas, with programs currently in the pre-clinical animal stage. GB Sciences operates in both North America and Europe, seeking to bring innovative, plant-based solutions to address unmet medical needs. Their strategy involves rigorous scientific investigation and the development of proprietary formulations to create effective and safe therapies. With a small team of 2 employees, the company outsources many functions. GB Sciences is positioned to capitalize on the growing acceptance of plant-based medicines and the increasing demand for novel therapeutic options.
Qué hacen
- Researches and develops plant-based medicines.
- Focuses on cannabinoid-inspired therapies.
- Targets conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Develops complex therapeutic mixtures for the prescription drug market.
- Conducts pre-clinical animal studies to evaluate drug candidates.
- Seeks to create innovative and effective treatments for unmet medical needs.
- Operates in North America and Europe.
Modelo de Negocio
- Develops proprietary plant-based medicine formulations.
- Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
Contexto de la Industria
GB Sciences operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for plant-based medicines is expanding, driven by increasing consumer interest in natural and alternative therapies. However, the industry is also subject to stringent regulations and lengthy approval processes. GB Sciences competes with other biotechnology companies, including ACUS, BIOAF, EHOS, GSTC and HTDS, some of which have greater resources and more advanced clinical programs. Success in this industry requires strong scientific expertise, effective regulatory strategies, and substantial capital investment.
Clientes Clave
- Pharmaceutical companies seeking novel drug candidates.
- Patients with conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Healthcare providers prescribing plant-based medicines.
Finanzas
Gráfico e información
Precio de la acción de GB Sciences, Inc. (GBLX): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Thursday
· 14 nov 2019
-
Stocks That Hit 52-Week Lows On Friday
· 8 nov 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· 15 oct 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GBLX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GBLX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GBLX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Andrea Small-Howard
Chief Executive Officer
Andrea Small-Howard serves as the Chief Executive Officer of GB Sciences, Inc. Her background includes experience in the pharmaceutical and biotechnology industries. She has a strong understanding of drug development, regulatory affairs, and commercialization strategies. Her expertise is crucial for guiding GB Sciences through its pre-clinical and clinical development programs. She is responsible for overseeing the company's overall strategy and operations, including research and development, business development, and investor relations.
Historial: Under Andrea Small-Howard's leadership, GB Sciences has focused on advancing its pre-clinical programs and expanding its intellectual property portfolio. She has been instrumental in securing funding and establishing strategic partnerships to support the company's growth. Her leadership is focused on driving innovation and creating value for shareholders through the development of novel plant-based medicines. She is managing 2 employees.
Información del mercado OTC de GBLX
The OTC Other tier represents the lowest tier of the OTC market, indicating that GB Sciences may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies on this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other tier status indicates potential financial or operational challenges.
- Dependence on external funding and partnerships.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property portfolio and competitive landscape.
- Evaluate the company's funding sources and cash runway.
- Understand the risks associated with investing in OTC-traded companies.
- Consult with a financial advisor before making any investment decisions.
- Confirm the company's good standing with the state of incorporation.
- Focus on research and development of plant-based medicines.
- Intellectual property portfolio covering various therapeutic areas.
- CEO with experience in the pharmaceutical and biotechnology industries.
- Company incorporated in 2001.
Acciones de GB Sciences, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar GBLX?
GB Sciences, Inc. (GBLX) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Focus on plant-based medicines.. Riesgo principal a monitorear: Potential: Failure to secure funding for clinical trials.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GBLX?
GBLX actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GBLX?
Los precios de GBLX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GBLX?
La cobertura de analistas para GBLX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GBLX?
Las categorías de riesgo para GBLX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to secure funding for clinical trials.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GBLX?
La relación P/E para GBLX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GBLX sobrevalorada o infravalorada?
Determinar si GB Sciences, Inc. (GBLX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GBLX?
GB Sciences, Inc. (GBLX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available company information and may be limited due to the company's OTC listing.
- AI analysis pending for GBLX.